By activating downstream arousal pathways of OX2R, these agonists not only simultaneously improve EDS, cataplexy, and nocturnal sleep fragmentation, but also enhance overall wakefulness quality—including heightened attention and reduced anxiety. Here, HCRTR2 is linked to Ehlers-Danlos syndrome.